Search
BridgeBio Oncology Therapeutics Ord Shs
BBOTAdd to Watchlist
2.560USD
+0.360+16.36%
Close 11-11 16:00（ET）
205.24MMarket Cap
12.68P/E TTM
After-hours 16:22 (ET)2.500USD-0.055-2.15%
After-hours 16:22 (ET)BBOT Analyst Recommendation Trends
In the current month, BBOT has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BBOT average Analyst price target in the last month is 20.667.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
4
4
4
4
4
4
4
4
7
7
7
6
6
5
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11
11
11
10
10
9
9
9
Financial Forecasting
Based on analysts' estimates, BBOT EPS is projected to reach -0.668 in FY2026Q4, following reported EPS of -0.426 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.53
-0.57
-0.69
-0.67
-0.64
Actual
-0.53
-0.71
-0.43
--
--
Surprise
+0.17%
-24.75%
+38.23%
--
--
FAQs
How have BridgeBio Oncology Therapeutics Ord ShsBBOT's recent earnings per share performed?
The market expectation was USD -0.43, while BridgeBio Oncology Therapeutics Ord ShsBBOT's earnings per share (EPS) for the previous quarter was USD -0.71. EPS for the next quarter is expected at USD -0.67.
What is the analyst rating for BridgeBio Oncology Therapeutics Ord Shs?
Based on the ratings of BridgeBio Oncology Therapeutics Ord Shs's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.